In prostate cancer, the prostate-specific antigen (PSA) is significantly increased and continues to increase as the tumor grows. The malignant prostate tumors have this antigen on their surface, on the membranes as prostate-specific membrane antigen (PMSA), other tumors or healthy tissue do not carry this antigen. In the Lu-177 PSMA procedure, the patient is administered substances that are accumulated by the tumors or metastases because they combine with the PSMA but do not adhere to healthy tissue.

Therapy with Lutetium 177 is performed in several cycles with an interval of eight weeks.

Our observations show that good to very good results were achieved after two to three courses of treatment, which corresponds to a significant decrease in the tumor marker. Even in patients who have already developed bone metastases, lymph node metastases or local recurrence in the prostate, a decrease in tumor foci was determined.

This therapy is especially suitable for patients with advanced prostate cancer following standard treatments such as anti-hormone therapy, chemotherapy, and radiation therapy. Side effects are insignificant and the therapy is very well tolerated.